{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:57:14Z","timestamp":1789873034371,"version":"4.0.1"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972265"],"award-info":[{"award-number":["81972265"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170602"],"award-info":[{"award-number":["82170602"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["20200201324JC"],"award-info":[{"award-number":["20200201324JC"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005227","name":"Jilin Department of Health","doi-asserted-by":"publisher","award":["JLSWSRCZX2021-079"],"award-info":[{"award-number":["JLSWSRCZX2021-079"]}],"id":[{"id":"10.13039\/501100005227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00018-022-04509-6","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T12:08:19Z","timestamp":1660738099000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease"],"prefix":"10.1007","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2484-1635","authenticated-orcid":false,"given":"Yali","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8590-6706","authenticated-orcid":false,"given":"Yanhang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"4509_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/nu13093145","author":"I Sohi","year":"2021","unstructured":"Sohi I, Franklin A, Chrystoja B, Wettlaufer A, Rehm J, Shield K (2021) The global impact of alcohol consumption on premature mortality and health in 2016. Nutrients. https:\/\/doi.org\/10.3390\/nu13093145","journal-title":"Nutrients"},{"key":"4509_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","volume":"3","author":"T Akinyemiju","year":"2017","unstructured":"Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, Artaman A, Ayele TA, Barac A, Bensenor I, Berhane A, Bhutta Z, Castillo-Rivas J, Chitheer A, Choi JY, Cowie B, Dandona L et al (2017) The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 3:1683\u20131691. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3055","journal-title":"JAMA Oncol"},{"key":"4509_CR3","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1053\/j.gastro.2011.09.002","volume":"141","author":"B Gao","year":"2011","unstructured":"Gao B, Bataller R (2011) Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 141:1572\u20131585. https:\/\/doi.org\/10.1053\/j.gastro.2011.09.002","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"4509_CR4","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1194\/jlr.R800026-JLR200","volume":"50","author":"DW Russell","year":"2009","unstructured":"Russell DW (2009) Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res 50(Suppl):S120-125. https:\/\/doi.org\/10.1194\/jlr.R800026-JLR200","journal-title":"J Lipid Res"},{"key":"4509_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrgastro.2017.119","volume":"15","author":"W Jia","year":"2018","unstructured":"Jia W, Xie G, Jia W (2018) Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol 15:111\u2013128. https:\/\/doi.org\/10.1038\/nrgastro.2017.119","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4509_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00566-7","author":"CD Fuchs","year":"2022","unstructured":"Fuchs CD, Trauner M (2022) Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nat Rev Gastroenterol Hepatol. https:\/\/doi.org\/10.1038\/s41575-021-00566-7","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4509_CR7","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","volume":"48","author":"I Kim","year":"2007","unstructured":"Kim I, Ahn SH, Inagaki T, Choi M, Ito S, Guo GL, Kliewer SA, Gonzalez FJ (2007) Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res 48:2664\u20132672. https:\/\/doi.org\/10.1194\/jlr.M700330-JLR200","journal-title":"J Lipid Res"},{"key":"4509_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","volume":"18","author":"L Sun","year":"2021","unstructured":"Sun L, Cai J, Gonzalez FJ (2021) The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Nat Rev Gastroenterol Hepatol 18:335\u2013347. https:\/\/doi.org\/10.1038\/s41575-020-00404-2","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4509_CR9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/s1097-2765(00)00051-4","volume":"6","author":"B Goodwin","year":"2000","unstructured":"Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6:517\u2013526. https:\/\/doi.org\/10.1016\/s1097-2765(00)00051-4","journal-title":"Mol Cell"},{"key":"4509_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","volume":"2","author":"T Inagaki","year":"2005","unstructured":"Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2:217\u2013225. https:\/\/doi.org\/10.1016\/j.cmet.2005.09.001","journal-title":"Cell Metab"},{"key":"4509_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/hep.22627","volume":"49","author":"KH Song","year":"2009","unstructured":"Song KH, Li T, Owsley E, Strom S, Chiang JY (2009) Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 49:297\u2013305. https:\/\/doi.org\/10.1002\/hep.22627","journal-title":"Hepatology"},{"key":"4509_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bbrc.2013.11.057","volume":"443","author":"W Wu","year":"2014","unstructured":"Wu W, Zhu B, Peng X, Zhou M, Jia D, Gu J (2014) Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun 443:68\u201373. https:\/\/doi.org\/10.1016\/j.bbrc.2013.11.057","journal-title":"Biochem Biophys Res Commun"},{"key":"4509_CR13","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1096\/fj.13-231860","volume":"27","author":"G Xie","year":"2013","unstructured":"Xie G, Zhong W, Li H, Li Q, Qiu Y, Zheng X, Chen H, Zhao X, Zhang S, Zhou Z, Zeisel SH, Jia W (2013) Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption. Faseb J 27:3583\u20133593. https:\/\/doi.org\/10.1096\/fj.13-231860","journal-title":"Faseb J"},{"key":"4509_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068845","volume":"8","author":"D Chanda","year":"2013","unstructured":"Chanda D, Kim YH, Li T, Misra J, Kim DK, Kim JR, Kwon J, Jeong WI, Ahn SH, Park TS, Koo SH, Chiang JY, Lee CH, Choi HS (2013) Hepatic cannabinoid receptor type 1 mediates alcohol-induced regulation of bile acid enzyme genes expression via CREBH. PLoS ONE 8:e68845. https:\/\/doi.org\/10.1371\/journal.pone.0068845","journal-title":"PLoS ONE"},{"key":"4509_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/hep4.1020","volume":"1","author":"DJ Kang","year":"2017","unstructured":"Kang DJ, Hylemon PB, Gillevet PM, Sartor RB, Betrapally NS, Kakiyama G, Sikaroodi M, Takei H, Nittono H, Zhou H, Pandak WM, Yang J, Jiao C, Li X, Lippman HR, Heuman DM, Bajaj JS (2017) Gut microbial composition can differentially regulate bile acid synthesis in humanized mice. Hepatol Commun 1:61\u201370. https:\/\/doi.org\/10.1002\/hep4.1020","journal-title":"Hepatol Commun"},{"key":"4509_CR16","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jhep.2018.03.031","volume":"69","author":"K Brandl","year":"2018","unstructured":"Brandl K, Hartmann P, Jih LJ, Pizzo DP, Argemi J, Ventura-Cots M, Coulter S, Liddle C, Ling L, Rossi SJ, DePaoli AM, Loomba R, Mehal WZ, Fouts DE, Lucey MR, Bosques-Padilla F, Mathurin P, Louvet A, Garcia-Tsao G, Verna EC et al (2018) Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J Hepatol 69:396\u2013405. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.031","journal-title":"J Hepatol"},{"key":"4509_CR17","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/hep.28965","volume":"65","author":"PL Jansen","year":"2017","unstructured":"Jansen PL, Ghallab A, Vartak N, Reif R, Schaap FG, Hampe J, Hengstler JG (2017) The ascending pathophysiology of cholestatic liver disease. Hepatology 65:722\u2013738. https:\/\/doi.org\/10.1002\/hep.28965","journal-title":"Hepatology"},{"key":"4509_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9030469","author":"HL Doden","year":"2021","unstructured":"Doden HL, Ridlon JM (2021) Microbial hydroxysteroid dehydrogenases: from alpha to omega. Microorganisms. https:\/\/doi.org\/10.3390\/microorganisms9030469","journal-title":"Microorganisms"},{"key":"4509_CR19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/alcalc\/agaa005","volume":"55","author":"X Gong","year":"2020","unstructured":"Gong X, Zhang Q, Ruan Y, Hu M, Liu Z, Gong L (2020) Chronic alcohol consumption increased bile acid levels in enterohepatic circulation and reduced efficacy of irinotecan. Alcohol Alcohol 55:264\u2013277. https:\/\/doi.org\/10.1093\/alcalc\/agaa005","journal-title":"Alcohol Alcohol"},{"key":"4509_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00418-007-0277-7","volume":"127","author":"V Zinchuk","year":"2007","unstructured":"Zinchuk V, Zinchuk O, Akimaru K, Moriya F, Okada T (2007) Ethanol consumption alters expression and colocalization of bile salt export pump and multidrug resistance protein 2 in the rat. Histochem Cell Biol 127:503\u2013512. https:\/\/doi.org\/10.1007\/s00418-007-0277-7","journal-title":"Histochem Cell Biol"},{"key":"4509_CR21","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/ijc.30219","volume":"139","author":"G Xie","year":"2016","unstructured":"Xie G, Wang X, Huang F, Zhao A, Chen W, Yan J, Zhang Y, Lei S, Ge K, Zheng X, Liu J, Su M, Liu P, Jia W (2016) Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int J Cancer 139:1764\u20131775. https:\/\/doi.org\/10.1002\/ijc.30219","journal-title":"Int J Cancer"},{"key":"4509_CR22","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/hep.26187","volume":"57","author":"Y Chen","year":"2013","unstructured":"Chen Y, Song X, Valanejad L, Vasilenko A, More V, Qiu X, Chen W, Lai Y, Slitt A, Stoner M, Yan B, Deng R (2013) Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma. Hepatology 57:1530\u20131541. https:\/\/doi.org\/10.1002\/hep.26187","journal-title":"Hepatology"},{"key":"4509_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.109847","volume":"356","author":"W Chen","year":"2022","unstructured":"Chen W, Zhang Q, Ding M, Yao J, Guo Y, Yan W, Yu S, Shen Q, Huang M, Zheng Y, Lin Y, Wang Y, Liu Z, Lu L (2022) Alcohol triggered bile acid disequilibrium by suppressing BSEP to sustain hepatocellular carcinoma progression. Chem Biol Interact 356:109847. https:\/\/doi.org\/10.1016\/j.cbi.2022.109847","journal-title":"Chem Biol Interact"},{"key":"4509_CR24","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","volume":"575","author":"Y Duan","year":"2019","unstructured":"Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, White RC, Clarke TH, Nguyen K, Torralba M, Shao Y, Liu J, Hernandez-Morales A, Lessor L, Rahman IR, Miyamoto Y, Ly M, Gao B, Sun W, Kiesel R et al (2019) Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 575:505\u2013511. https:\/\/doi.org\/10.1038\/s41586-019-1742-x","journal-title":"Nature"},{"key":"4509_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jhep.2019.09.029","volume":"72","author":"H Chu","year":"2020","unstructured":"Chu H, Duan Y, Lang S, Jiang L, Wang Y, Llorente C, Liu J, Mogavero S, Bosques-Padilla F, Abraldes JG, Vargas V, Tu XM, Yang L, Hou X, Hube B, St\u00e4rkel P, Schnabl B (2020) The Candida albicans exotoxin Candidalysin promotes alcohol-associated liver disease. J Hepatol 72:391\u2013400. https:\/\/doi.org\/10.1016\/j.jhep.2019.09.029","journal-title":"J Hepatol"},{"key":"4509_CR26","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/hep.30832","volume":"71","author":"S Lang","year":"2020","unstructured":"Lang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura-Cots M, Abraldes JG, Bosques-Padilla F, Verna EC, Brown RS Jr, Vargas V, Altamirano J, Caballer\u00eda J, Shawcross D, Lucey MR, Louvet A, Mathurin P, Garcia-Tsao G, Ho SB, Tu XM et al (2020) Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology 71:522\u2013538. https:\/\/doi.org\/10.1002\/hep.30832","journal-title":"Hepatology"},{"key":"4509_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","volume":"576","author":"S Hang","year":"2019","unstructured":"Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, Ha S, Nelson BN, Kelly SP, Wu L, Zheng Y, Longman RS, Rastinejad F, Devlin AS, Krout MR, Fischbach MA, Littman DR, Huh JR (2019) Bile acid metabolites control T(h)17 and T(reg) cell differentiation. Nature 576:143\u2013148. https:\/\/doi.org\/10.1038\/s41586-019-1785-z","journal-title":"Nature"},{"key":"4509_CR28","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41586-022-04480-z","volume":"603","author":"D Paik","year":"2022","unstructured":"Paik D, Yao L, Zhang Y, Bae S, D\u2019Agostino GD, Zhang M, Kim E, Franzosa EA, Avila-Pacheco J, Bisanz JE, Rakowski CK, Vlamakis H, Xavier RJ, Turnbaugh PJ, Longman RS, Krout MR, Clish CB, Rastinejad F, Huttenhower C, Huh JR et al (2022) Human gut bacteria produce T(H)17-modulating bile acid metabolites. Nature 603:907\u2013912. https:\/\/doi.org\/10.1038\/s41586-022-04480-z","journal-title":"Nature"},{"key":"4509_CR29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jhep.2018.10.023","volume":"70","author":"B Gao","year":"2019","unstructured":"Gao B, Ahmad MF, Nagy LE, Tsukamoto H (2019) Inflammatory pathways in alcoholic steatohepatitis. J Hepatol 70:249\u2013259. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.023","journal-title":"J Hepatol"},{"key":"4509_CR30","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/hep.22680","volume":"49","author":"A Lemmers","year":"2009","unstructured":"Lemmers A, Moreno C, Gustot T, Mar\u00e9chal R, Degr\u00e9 D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Le Moine O, Devi\u00e8re J (2009) The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 49:646\u2013657. https:\/\/doi.org\/10.1002\/hep.22680","journal-title":"Hepatology"},{"key":"4509_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055101","author":"S St\u00f8y","year":"2013","unstructured":"St\u00f8y S, Sandahl TD, Dige AK, Agnholt J, Rasmussen TK, Gr\u00f8nb\u00e6k H, Deleuran B, Vilstrup H (2013) Highest frequencies of interleukin-22-producing t helper cells in alcoholic hepatitis patients with a favourable short-term course. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0055101","journal-title":"PLoS ONE"},{"key":"4509_CR32","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/hepr.12173","volume":"44","author":"V Ortiz","year":"2014","unstructured":"Ortiz V, Wands JR (2014) Chronic ethanol diet increases regulatory t-cell activity and inhibits hepatitis c virus core-specific cellular immune responses in mice. Hepatol Res 44:788\u2013797. https:\/\/doi.org\/10.1111\/hepr.12173","journal-title":"Hepatol Res"},{"key":"4509_CR33","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41586-021-03832-5","volume":"599","author":"Y Sato","year":"2021","unstructured":"Sato Y, Atarashi K, Plichta DR, Arai Y, Sasajima S, Kearney SM, Suda W, Takeshita K, Sasaki T, Okamoto S, Skelly AN, Okamura Y, Vlamakis H, Li Y, Tanoue T, Takei H, Nittono H, Narushima S, Irie J, Itoh H et al (2021) Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians. Nature 599:458\u2013464. https:\/\/doi.org\/10.1038\/s41586-021-03832-5","journal-title":"Nature"},{"key":"4509_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41575-018-0099-1","volume":"16","author":"JS Bajaj","year":"2019","unstructured":"Bajaj JS (2019) Alcohol, liver disease and the gut microbiota. Nat Rev Gastroenterol Hepatol 16:235\u2013246. https:\/\/doi.org\/10.1038\/s41575-018-0099-1","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4509_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","volume":"24","author":"A Wahlstr\u00f6m","year":"2016","unstructured":"Wahlstr\u00f6m A, Sayin SI, Marschall HU, B\u00e4ckhed F (2016) Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab 24:41\u201350. https:\/\/doi.org\/10.1016\/j.cmet.2016.05.005","journal-title":"Cell Metab"},{"key":"4509_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/00952990.2019.1669629","volume":"46","author":"K Litwinowicz","year":"2020","unstructured":"Litwinowicz K, Choroszy M, Waszczuk E (2020) Changes in the composition of the human intestinal microbiome in alcohol use disorder: a systematic review. Am J Drug Alcohol Abuse 46:4\u201312. https:\/\/doi.org\/10.1080\/00952990.2019.1669629","journal-title":"Am J Drug Alcohol Abuse"},{"key":"4509_CR37","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/hep.29676","volume":"67","author":"P Hartmann","year":"2018","unstructured":"Hartmann P, Hochrath K, Horvath A, Chen P, Seebauer CT, Llorente C, Wang L, Alnouti Y, Fouts DE, St\u00e4rkel P, Loomba R, Coulter S, Liddle C, Yu RT, Ling L, Rossi SJ, DePaoli AM, Downes M, Evans RM, Brenner DA et al (2018) Modulation of the intestinal bile acid\/farnesoid X receptor\/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology 67:2150\u20132166. https:\/\/doi.org\/10.1002\/hep.29676","journal-title":"Hepatology"},{"key":"4509_CR38","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12072-022-10299-7","volume":"16","author":"R Shen","year":"2022","unstructured":"Shen R, Ke L, Li Q, Dang X, Shen S, Shen J, Li S, Liang L, Peng B, Kuang M, Ma Y, Yang Z, Hua Y (2022) Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma. Hepatol Int 16:396\u2013411. https:\/\/doi.org\/10.1007\/s12072-022-10299-7","journal-title":"Hepatol Int"},{"key":"4509_CR39","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-020-2396-4","volume":"582","author":"M Funabashi","year":"2020","unstructured":"Funabashi M, Grove TL, Wang M, Varma Y, McFadden ME, Brown LC, Guo C, Higginbottom S, Almo SC, Fischbach MA (2020) A metabolic pathway for bile acid dehydroxylation by the gut microbiome. Nature 582:566\u2013570. https:\/\/doi.org\/10.1038\/s41586-020-2396-4","journal-title":"Nature"},{"key":"4509_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.chembiol.2018.10.003","volume":"26","author":"JD Kang","year":"2019","unstructured":"Kang JD, Myers CJ, Harris SC, Kakiyama G, Lee IK, Yun BS, Matsuzaki K, Furukawa M, Min HK, Bajaj JS, Zhou H, Hylemon PB (2019) Bile acid 7\u03b1-dehydroxylating gut bacteria secrete antibiotics that inhibit Clostridium difficile: role of secondary bile acids. Cell Chem Biol 26:27-34.e24. https:\/\/doi.org\/10.1016\/j.chembiol.2018.10.003","journal-title":"Cell Chem Biol"},{"key":"4509_CR41","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.Cd-16-0932","volume":"7","author":"TM Loo","year":"2017","unstructured":"Loo TM, Kamachi F, Watanabe Y, Yoshimoto S, Kanda H, Arai Y, Nakajima-Takagi Y, Iwama A, Koga T, Sugimoto Y, Ozawa T, Nakamura M, Kumagai M, Watashi K, Taketo MM, Aoki T, Narumiya S, Oshima M, Arita M, Hara E et al (2017) Gut microbiota promotes obesity-associated liver cancer through PGE(2)-mediated suppression of antitumor immunity. Cancer Discov 7:522\u2013538. https:\/\/doi.org\/10.1158\/2159-8290.Cd-16-0932","journal-title":"Cancer Discov"},{"key":"4509_CR42","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan5931","author":"C Ma","year":"2018","unstructured":"Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, Agdashian D, Terabe M, Berzofsky JA, Fako V, Ritz T, Longerich T, Theriot CM, McCulloch JA, Roy S, Yuan W, Thovarai V, Sen SK, Ruchirawat M, Korangy F et al (2018) Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. https:\/\/doi.org\/10.1126\/science.aan5931","journal-title":"Science"},{"key":"4509_CR43","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.cell.2021.12.035","volume":"185","author":"WB Jin","year":"2022","unstructured":"Jin WB, Li TT, Huo D, Qu S, Li XV, Arifuzzaman M, Lima SF, Shi HQ, Wang A, Putzel GG, Longman RS, Artis D, Guo CJ (2022) Genetic manipulation of gut microbes enables single-gene interrogation in a complex microbiome. Cell 185:547-562.e522. https:\/\/doi.org\/10.1016\/j.cell.2021.12.035","journal-title":"Cell"},{"key":"4509_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8030050","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Zhang T, Kusumanchi P, Han S, Yang Z, Liangpunsakul S (2020) Alcohol metabolizing enzymes, microsomal ethanol oxidizing system, cytochrome p450 2E1, catalase, and aldehyde dehydrogenase in alcohol-associated liver disease. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines8030050","journal-title":"Biomedicines"},{"key":"4509_CR45","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1194\/jlr.M039404","volume":"54","author":"C Langhi","year":"2013","unstructured":"Langhi C, Pedraz-Cuesta E, Haro D, Marrero PF, Rodr\u00edguez JC (2013) Regulation of human class I alcohol dehydrogenases by bile acids. J Lipid Res 54:2475\u20132484. https:\/\/doi.org\/10.1194\/jlr.M039404","journal-title":"J Lipid Res"},{"key":"4509_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cbi.2014.03.014","volume":"217","author":"FA L\u00edvero","year":"2014","unstructured":"L\u00edvero FA, Stolf AM, Dreifuss AA, Bastos-Pereira AL, Chicorski R, de Oliveira LG, de Souza CE, Fabossi IA, Rabitto IS, Gremski LH, Henneberg R, Telles JE, Oude Elferink RP, Acco A (2014) The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice. Chem Biol Interact 217:19\u201327. https:\/\/doi.org\/10.1016\/j.cbi.2014.03.014","journal-title":"Chem Biol Interact"},{"key":"4509_CR47","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.dld.2018.12.026","volume":"51","author":"B Kong","year":"2019","unstructured":"Kong B, Zhang M, Huang M, Rizzolo D, Armstrong LE, Schumacher JD, Chow MD, Lee YH, Guo GL (2019) FXR deficiency alters bile acid pool composition and exacerbates chronic alcohol induced liver injury. Dig Liver Dis 51:570\u2013576. https:\/\/doi.org\/10.1016\/j.dld.2018.12.026","journal-title":"Dig Liver Dis"},{"key":"4509_CR48","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.dld.2018.04.009","volume":"50","author":"M Zhang","year":"2018","unstructured":"Zhang M, Kong B, Huang M, Wan R, Armstrong LE, Schumacher JD, Rizzolo D, Chow MD, Lee YH, Guo GL (2018) FXR deletion in hepatocytes does not affect the severity of alcoholic liver disease in mice. Dig Liver Dis 50:1068\u20131075. https:\/\/doi.org\/10.1016\/j.dld.2018.04.009","journal-title":"Dig Liver Dis"},{"key":"4509_CR49","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/s41374-020-0439-y","volume":"100","author":"M Huang","year":"2020","unstructured":"Huang M, Kong B, Zhang M, Rizzolo D, Armstrong LE, Schumacher JD, Chow MD, Lee YH, Joseph LB, Stofan M, Zhang L, Guo GL (2020) Enhanced alcoholic liver disease in mice with intestine-specific farnesoid X receptor deficiency. Lab Invest 100:1158\u20131168. https:\/\/doi.org\/10.1038\/s41374-020-0439-y","journal-title":"Lab Invest"},{"key":"4509_CR50","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1101\/gad.1467506","volume":"20","author":"MC Haigis","year":"2006","unstructured":"Haigis MC, Guarente LP (2006) Mammalian sirtuins\u2013emerging roles in physiology, aging, and calorie restriction. Genes Dev 20:2913\u20132921. https:\/\/doi.org\/10.1101\/gad.1467506","journal-title":"Genes Dev"},{"key":"4509_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.02.030","author":"R Sun","year":"2022","unstructured":"Sun R, Zhang Z, Bao R, Guo X, Gu Y, Yang W, Wei J, Chen X, Tong L, Meng J, Zhong C, Zhang C, Zhang J, Sun Y, Ling C, Tong X, Yu FX, Yu H, Qu W, Zhao B et al (2022) Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2022.02.030","journal-title":"J Hepatol"},{"key":"4509_CR52","doi-asserted-by":"publisher","first-page":"3589525","DOI":"10.1155\/2022\/3589525","volume":"2022","author":"W Deng","year":"2022","unstructured":"Deng W, Fan W, Tang T, Wan H, Zhao S, Tan Y, Oware KA, Tan J, Li J, Qu S (2022) Farnesoid X receptor deficiency induces hepatic lipid and glucose metabolism disorder via regulation of pyruvate dehydrogenase kinase 4. Oxid Med Cell Longev 2022:3589525. https:\/\/doi.org\/10.1155\/2022\/3589525","journal-title":"Oxid Med Cell Longev"},{"key":"4509_CR53","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/s0168-8278(00)80242-1","volume":"32","author":"A Parlesak","year":"2000","unstructured":"Parlesak A, Sch\u00e4fer C, Sch\u00fctz T, Bode JC, Bode C (2000) Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol 32:742\u2013747. https:\/\/doi.org\/10.1016\/s0168-8278(00)80242-1","journal-title":"J Hepatol"},{"key":"4509_CR54","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida T, Friedman SL (2017) Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 14:397\u2013411. https:\/\/doi.org\/10.1038\/nrgastro.2017.38","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4509_CR55","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jhep.2021.12.019","volume":"76","author":"A Garrido","year":"2022","unstructured":"Garrido A, Kim E, Teijeiro A, S\u00e1nchez S\u00e1nchez P, Gallo R, Nair A, Matamala Montoya M, Perna C, Vicent GP, Mu\u00f1oz J, Campos-Olivas R, Melms JC, Izar B, Schwabe RF, Djouder N (2022) Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis. J Hepatol 76:850\u2013861. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.019","journal-title":"J Hepatol"},{"key":"4509_CR56","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1073\/pnas.0509592103","volume":"103","author":"T Inagaki","year":"2006","unstructured":"Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, Mangelsdorf DJ, Kliewer SA (2006) Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 103:3920\u20133925. https:\/\/doi.org\/10.1073\/pnas.0509592103","journal-title":"Proc Natl Acad Sci USA"},{"key":"4509_CR57","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1042\/cs20171055","volume":"132","author":"P St\u00e4rkel","year":"2018","unstructured":"St\u00e4rkel P, Leclercq S, de Timary P, Schnabl B (2018) Intestinal dysbiosis and permeability: the Yin and Yang in alcohol dependence and alcoholic liver disease. Clin Sci (Lond) 132:199\u2013212. https:\/\/doi.org\/10.1042\/cs20171055","journal-title":"Clin Sci (Lond)"},{"key":"4509_CR58","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1124\/jpet.111.179390","volume":"338","author":"A Wolfe","year":"2011","unstructured":"Wolfe A, Thomas A, Edwards G, Jaseja R, Guo GL, Apte U (2011) Increased activation of the Wnt\/\u03b2-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther 338:12\u201321. https:\/\/doi.org\/10.1124\/jpet.111.179390","journal-title":"J Pharmacol Exp Ther"},{"key":"4509_CR59","doi-asserted-by":"publisher","first-page":"G929","DOI":"10.1152\/ajpgi.00315.2013","volume":"306","author":"G Kakiyama","year":"2014","unstructured":"Kakiyama G, Hylemon PB, Zhou H, Pandak WM, Heuman DM, Kang DJ, Takei H, Nittono H, Ridlon JM, Fuchs M, Gurley EC, Wang Y, Liu R, Sanyal AJ, Gillevet PM, Bajaj JS (2014) Colonic inflammation and secondary bile acids in alcoholic cirrhosis. Am J Physiol Gastrointest Liver Physiol 306:G929-937. https:\/\/doi.org\/10.1152\/ajpgi.00315.2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"4509_CR60","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/hep.22771","volume":"49","author":"FG Schaap","year":"2009","unstructured":"Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL (2009) High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49:1228\u20131235. https:\/\/doi.org\/10.1002\/hep.22771","journal-title":"Hepatology"},{"key":"4509_CR61","doi-asserted-by":"publisher","first-page":"13462","DOI":"10.1038\/srep13462","volume":"5","author":"E Wunsch","year":"2015","unstructured":"Wunsch E, Milkiewicz M, Wasik U, Trottier J, Kempi\u0144ska-Podhorodecka A, Elias E, Barbier O, Milkiewicz P (2015) Expression of hepatic fibroblast growth factor 19 is enhanced in primary biliary cirrhosis and correlates with severity of the disease. Sci Rep 5:13462. https:\/\/doi.org\/10.1038\/srep13462","journal-title":"Sci Rep"},{"key":"4509_CR62","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hep.28257","volume":"63","author":"M Zhou","year":"2016","unstructured":"Zhou M, Learned RM, Rossi SJ, DePaoli AM, Tian H, Ling L (2016) Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology 63:914\u2013929. https:\/\/doi.org\/10.1002\/hep.28257","journal-title":"Hepatology"},{"key":"4509_CR63","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0016-5085(78)90401-8","volume":"75","author":"WC Maddrey","year":"1978","unstructured":"Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr (1978) Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 75:193\u2013199","journal-title":"Gastroenterology"},{"key":"4509_CR64","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1111\/j.1572-0241.2008.02104.x","volume":"103","author":"M Dominguez","year":"2008","unstructured":"Dominguez M, Rinc\u00f3n D, Abraldes JG, Miquel R, Colmenero J, Bellot P, Garc\u00eda-Pag\u00e1n JC, Fern\u00e1ndez R, Moreno M, Ba\u00f1ares R, Arroyo V, Caballer\u00eda J, Gin\u00e8s P, Bataller R (2008) A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 103:2747\u20132756. https:\/\/doi.org\/10.1111\/j.1572-0241.2008.02104.x","journal-title":"Am J Gastroenterol"},{"key":"4509_CR65","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","volume":"372","author":"MR Thursz","year":"2015","unstructured":"Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, Downs N, Gleeson D, MacGilchrist A, Grant A, Hood S, Masson S, McCune A, Mellor J, O\u2019Grady J, Patch D, Ratcliffe I, Roderick P, Stanton L, Vergis N et al (2015) Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 372:1619\u20131628. https:\/\/doi.org\/10.1056\/NEJMoa1412278","journal-title":"N Engl J Med"},{"key":"4509_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324295","author":"M Ventura-Cots","year":"2022","unstructured":"Ventura-Cots M, Argemi J, Jones PD, Lackner C, El Hag M, Abraldes JG, Alvarado E, Clemente A, Ravi S, Alves A, Alboraie M, Altamirano J, Barace S, Bosques F, Brown R, Caballeria J, Cabezas J, Carvalhana S, Cortez-Pinto H, Costa A et al (2022) Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut. https:\/\/doi.org\/10.1136\/gutjnl-2021-324295","journal-title":"Gut"},{"key":"4509_CR67","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/gutjnl-2015-310585","volume":"65","author":"M Llopis","year":"2016","unstructured":"Llopis M, Cassard AM, Wrzosek L, Boschat L, Bruneau A, Ferrere G, Puchois V, Martin JC, Lepage P, Le Roy T, Lef\u00e8vre L, Langelier B, Cailleux F, Gonz\u00e1lez-Castro AM, Rabot S, Gaudin F, Agostini H, Pr\u00e9vot S, Berrebi D, Ciocan D et al (2016) Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 65:830\u2013839. https:\/\/doi.org\/10.1136\/gutjnl-2015-310585","journal-title":"Gut"},{"key":"4509_CR68","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/apt.14949","volume":"48","author":"D Ciocan","year":"2018","unstructured":"Ciocan D, Voican CS, Wrzosek L, Hugot C, Rainteau D, Humbert L, Cassard AM, Perlemuter G (2018) Bile acid homeostasis and intestinal dysbiosis in alcoholic hepatitis. Aliment Pharmacol Ther 48:961\u2013974. https:\/\/doi.org\/10.1111\/apt.14949","journal-title":"Aliment Pharmacol Ther"},{"key":"4509_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1885","author":"MD Muthiah","year":"2022","unstructured":"Muthiah MD, Smirnova E, Puri P, Chalasani N, Shah VH, Kiani C, Taylor S, Mirshahi F, Sanyal AJ (2022) Development of alcohol-associated hepatitis is associated with specific changes in gut-modified bile acids. Hepatol Commun. https:\/\/doi.org\/10.1002\/hep4.1885","journal-title":"Hepatol Commun"},{"key":"4509_CR70","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/hep4.1671","volume":"5","author":"L He","year":"2021","unstructured":"He L, Vatsalya V, Ma X, Zhang J, Yin X, Kim S, Feng W, McClain CJ, Zhang X (2021) Metabolic profiling of bile acids in the urine of patients with alcohol-associated liver disease. Hepatol Commun 5:798\u2013811. https:\/\/doi.org\/10.1002\/hep4.1671","journal-title":"Hepatol Commun"},{"key":"4509_CR71","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2021.7683","volume":"326","author":"AK Singal","year":"2021","unstructured":"Singal AK, Mathurin P (2021) Diagnosis and treatment of alcohol-associated liver disease: a review. JAMA 326:165\u2013176. https:\/\/doi.org\/10.1001\/jama.2021.7683","journal-title":"JAMA"},{"key":"4509_CR72","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1111\/acer.13498","volume":"41","author":"JS Bajaj","year":"2017","unstructured":"Bajaj JS, Kakiyama G, Zhao D, Takei H, Fagan A, Hylemon P, Zhou H, Pandak WM, Nittono H, Fiehn O, Salzman N, Holtz M, Simpson P, Gavis EA, Heuman DM, Liu R, Kang DJ, Sikaroodi M, Gillevet PM (2017) Continued alcohol misuse in human cirrhosis is associated with an impaired gut-liver axis. Alcohol Clin Exp Res 41:1857\u20131865. https:\/\/doi.org\/10.1111\/acer.13498","journal-title":"Alcohol Clin Exp Res"},{"key":"4509_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.735","volume":"12","author":"I Balazs","year":"2022","unstructured":"Balazs I, Horvath A, Leber B, Feldbacher N, Sattler W, Rainer F, Fauler G, Vermeren S, Stadlbauer V (2022) Serum bile acids in liver cirrhosis promote neutrophil dysfunction. Clin Transl Med 12:e735. https:\/\/doi.org\/10.1002\/ctm2.735","journal-title":"Clin Transl Med"},{"key":"4509_CR74","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/hep.27779","volume":"62","author":"J Michelena","year":"2015","unstructured":"Michelena J, Altamirano J, Abraldes JG, Aff\u00f2 S, Morales-Ibanez O, Sancho-Bru P, Dominguez M, Garc\u00eda-Pag\u00e1n JC, Fern\u00e1ndez J, Arroyo V, Gin\u00e8s P, Louvet A, Mathurin P, Mehal WZ, Caballer\u00eda J, Bataller R (2015) Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology 62:762\u2013772. https:\/\/doi.org\/10.1002\/hep.27779","journal-title":"Hepatology"},{"key":"4509_CR75","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jhep.2012.06.026","volume":"57","author":"R Jalan","year":"2012","unstructured":"Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, Arroyo V, Kamath PS (2012) Acute-on chronic liver failure. J Hepatol 57:1336\u20131348. https:\/\/doi.org\/10.1016\/j.jhep.2012.06.026","journal-title":"J Hepatol"},{"key":"4509_CR76","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/liv.13201","volume":"37","author":"T Horvatits","year":"2017","unstructured":"Horvatits T, Drolz A, Roedl K, Rutter K, Ferlitsch A, Fauler G, Trauner M, Fuhrmann V (2017) Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis. Liver Int 37:224\u2013231. https:\/\/doi.org\/10.1111\/liv.13201","journal-title":"Liver Int"},{"key":"4509_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157898","author":"G Christidis","year":"2021","unstructured":"Christidis G, Karatayli E, Hall RA, Weber SN, Reichert MC, Hohl M, Qiao S, Boehm U, L\u00fctjohann D, Lammert F, Karatayli SC (2021) Fibroblast growth factor 21 response in a preclinical alcohol model of acute-on-chronic liver injury. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22157898","journal-title":"Int J Mol Sci"},{"key":"4509_CR78","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nprot.2013.032","volume":"8","author":"A Bertola","year":"2013","unstructured":"Bertola A, Mathews S, Ki SH, Wang H, Gao B (2013) Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc 8:627\u2013637. https:\/\/doi.org\/10.1038\/nprot.2013.032","journal-title":"Nat Protoc"},{"key":"4509_CR79","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.bbadis.2018.11.008","volume":"1865","author":"E Karatayli","year":"2019","unstructured":"Karatayli E, Hall RA, Weber SN, Dooley S, Lammert F (2019) Effect of alcohol on the interleukin 6-mediated inflammatory response in a new mouse model of acute-on-chronic liver injury. Biochim Biophys Acta Mol Basis Dis 1865:298\u2013307. https:\/\/doi.org\/10.1016\/j.bbadis.2018.11.008","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"4509_CR80","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.molmet.2018.03.010","volume":"11","author":"S S\u00f8berg","year":"2018","unstructured":"S\u00f8berg S, Andersen ES, Dalsgaard NB, Jarlhelt I, Hansen NL, Hoffmann N, Vilsb\u00f8ll T, Chenchar A, Jensen M, Grevengoed TJ, Trammell SAJ, Knop FK, Gillum MP (2018) FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest. Mol Metab 11:96\u2013103. https:\/\/doi.org\/10.1016\/j.molmet.2018.03.010","journal-title":"Mol Metab"},{"key":"4509_CR81","doi-asserted-by":"publisher","unstructured":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: a systematic analysis for the global burden of disease study 2016 (2017). Lancet 390:1151\u20131210. https:\/\/doi.org\/10.1016\/s0140-6736(17)32152-9","DOI":"10.1016\/s0140-6736(17)32152-9"},{"key":"4509_CR82","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jhep.2010.01.034","volume":"53","author":"L Pawlikowska","year":"2010","unstructured":"Pawlikowska L, Strautnieks S, Jankowska I, Czubkowski P, Emerick K, Antoniou A, Wanty C, Fischler B, Jacquemin E, Wali S, Blanchard S, Nielsen IM, Bourke B, McQuaid S, Lacaille F, Byrne JA, van Eerde AM, Kolho KL, Klomp L, Houwen R et al (2010) Differences in presentation and progression between severe FIC1 and BSEP deficiencies. J Hepatol 53:170\u2013178. https:\/\/doi.org\/10.1016\/j.jhep.2010.01.034","journal-title":"J Hepatol"},{"key":"4509_CR83","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/hep.25630","volume":"56","author":"N Tanaka","year":"2012","unstructured":"Tanaka N, Matsubara T, Krausz KW, Patterson AD, Gonzalez FJ (2012) Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 56:118\u2013129. https:\/\/doi.org\/10.1002\/hep.25630","journal-title":"Hepatology"},{"key":"4509_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154457","volume":"116","author":"N Nimer","year":"2021","unstructured":"Nimer N, Choucair I, Wang Z, Nemet I, Li L, Gukasyan J, Weeks TL, Alkhouri N, Zein N, Tang WHW, Fischbach MA, Brown JM, Allayee H, Dasarathy S, Gogonea V, Hazen SL (2021) Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Metabolism 116:154457. https:\/\/doi.org\/10.1016\/j.metabol.2020.154457","journal-title":"Metabolism"},{"key":"4509_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.02.016","author":"NR Montanari","year":"2022","unstructured":"Montanari NR, Ram\u00edrez R, Aggarwal A, van Buuren N, Doukas M, Moon C, Turner S, Diehl L, Li L, Debes JD, Feierbach B, Boonstra A (2022) Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2022.02.016","journal-title":"J Hepatol"},{"key":"4509_CR86","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","volume":"17","author":"AF Gulamhusein","year":"2020","unstructured":"Gulamhusein AF, Hirschfield GM (2020) Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol 17:93\u2013110. https:\/\/doi.org\/10.1038\/s41575-019-0226-7","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4509_CR87","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jhep.2020.01.014","volume":"72","author":"K Panzitt","year":"2020","unstructured":"Panzitt K, Jungwirth E, Krones E, Lee JM, Pollheimer M, Thallinger GG, Kolb-Lenz D, Xiao R, Thorell A, Trauner M, Fickert P, Marschall HU, Moore DD, Wagner M (2020) FXR-dependent rubicon induction impairs autophagy in models of human cholestasis. J Hepatol 72:1122\u20131131. https:\/\/doi.org\/10.1016\/j.jhep.2020.01.014","journal-title":"J Hepatol"},{"key":"4509_CR88","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.canlet.2019.04.009","volume":"454","author":"L Gao","year":"2019","unstructured":"Gao L, Lv G, Li R, Liu WT, Zong C, Ye F, Li XY, Yang X, Jiang JH, Hou XJ, Jing YY, Han ZP, Wei LX (2019) Glycochenodeoxycholate promotes hepatocellular carcinoma invasion and migration by AMPK\/Mtor dependent autophagy activation. Cancer Lett 454:215\u2013223. https:\/\/doi.org\/10.1016\/j.canlet.2019.04.009","journal-title":"Cancer Lett"},{"key":"4509_CR89","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/s2468-1253(19)30094-9","volume":"4","author":"M Trauner","year":"2019","unstructured":"Trauner M, Nevens F, Shiffman ML, Drenth JPH, Bowlus CL, Vargas V, Andreone P, Hirschfield GM, Pencek R, Malecha ES, MacConell L, Shapiro D (2019) Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol 4:445\u2013453. https:\/\/doi.org\/10.1016\/s2468-1253(19)30094-9","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4509_CR90","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/hep.26939","volume":"59","author":"L Verbeke","year":"2014","unstructured":"Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, Elst IV, Windmolders P, Vanuytsel T, Nevens F, Laleman W (2014) Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59:2286\u20132298. https:\/\/doi.org\/10.1002\/hep.26939","journal-title":"Hepatology"},{"key":"4509_CR91","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1002\/hep.31613","volume":"73","author":"L Smets","year":"2021","unstructured":"Smets L, Verbeek J, Korf H, van der Merwe S, Nevens F (2021) Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and Bezafibrate. Hepatology 73:2598\u20132600. https:\/\/doi.org\/10.1002\/hep.31613","journal-title":"Hepatology"},{"key":"4509_CR92","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","volume":"73","author":"KV Kowdley","year":"2020","unstructured":"Kowdley KV, Vuppalanchi R, Levy C, Floreani A, Andreone P, LaRusso NF, Shrestha R, Trotter J, Goldberg D, Rushbrook S, Hirschfield GM, Schiano T, Jin Y, Pencek R, MacConell L, Shapiro D, Bowlus CL (2020) A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. J Hepatol 73:94\u2013101. https:\/\/doi.org\/10.1016\/j.jhep.2020.02.033","journal-title":"J Hepatol"},{"key":"4509_CR93","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","volume":"76","author":"ME Rinella","year":"2022","unstructured":"Rinella ME, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V (2022) Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the regenerate study. J Hepatol 76:536\u2013548. https:\/\/doi.org\/10.1016\/j.jhep.2021.10.029","journal-title":"J Hepatol"},{"key":"4509_CR94","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/s0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P et al (2019) Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394:2184\u20132196. https:\/\/doi.org\/10.1016\/s0140-6736(19)33041-7","journal-title":"Lancet"},{"key":"4509_CR95","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jhep.2018.05.012","volume":"69","author":"TB Peeraphatdit","year":"2018","unstructured":"Peeraphatdit TB, Simonetto DA, Shah VH (2018) Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis. J Hepatol 69:275\u2013277. https:\/\/doi.org\/10.1016\/j.jhep.2018.05.012","journal-title":"J Hepatol"},{"key":"4509_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114430","volume":"186","author":"Y Yin","year":"2021","unstructured":"Yin Y, Wang M, Gu W, Chen L (2021) Intestine-specific FXR agonists as potential therapeutic agents for colorectal cancer. Biochem Pharmacol 186:114430. https:\/\/doi.org\/10.1016\/j.bcp.2021.114430","journal-title":"Biochem Pharmacol"},{"key":"4509_CR97","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/hep.29857","volume":"68","author":"P Pathak","year":"2018","unstructured":"Pathak P, Xie C, Nichols RG, Ferrell JM, Boehme S, Krausz KW, Patterson AD, Gonzalez FJ, Chiang JYL (2018) Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology 68:1574\u20131588. https:\/\/doi.org\/10.1002\/hep.29857","journal-title":"Hepatology"},{"key":"4509_CR98","doi-asserted-by":"publisher","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","volume":"318","author":"JYL Chiang","year":"2020","unstructured":"Chiang JYL, Ferrell JM (2020) Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol Gastrointest Liver Physiol 318:G554\u2013G573. https:\/\/doi.org\/10.1152\/ajpgi.00223.2019","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"4509_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/cells8060536","author":"A Raja","year":"2019","unstructured":"Raja A, Park I, Haq F, Ahn SM (2019) FGF19-FGR4 signaling in hepatocellular carcinoma. Cells. https:\/\/doi.org\/10.3390\/cells8060536","journal-title":"Cells"},{"key":"4509_CR100","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1158\/0008-5472.Can-14-0208","volume":"74","author":"M Zhou","year":"2014","unstructured":"Zhou M, Wang X, Phung V, Lindhout DA, Mondal K, Hsu JY, Yang H, Humphrey M, Ding X, Arora T, Learned RM, DePaoli AM, Tian H, Ling L (2014) Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res 74:3306\u20133316. https:\/\/doi.org\/10.1158\/0008-5472.Can-14-0208","journal-title":"Cancer Res"},{"key":"4509_CR101","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","volume":"70","author":"GM Hirschfield","year":"2019","unstructured":"Hirschfield GM, Chazouill\u00e8res O, Drenth JP, Thorburn D, Harrison SA, Landis CS, Mayo MJ, Muir AJ, Trotter JF, Leeming DJ, Karsdal MA, Jaros MJ, Ling L, Kim KH, Rossi SJ, Somaratne RM, DePaoli AM, Beuers U (2019) Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol 70:483\u2013493. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.035","journal-title":"J Hepatol"},{"key":"4509_CR102","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","volume":"160","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Neff G, Guy CD, Bashir MR, Paredes AH, Frias JP, Younes Z, Trotter JF, Gunn NT, Moussa SE, Kohli A, Nelson K, Gottwald M, Chang WCG, Yan AZ, DePaoli AM, Ling L, Lieu HD (2021) Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology 160:219\u2013231. https:\/\/doi.org\/10.1053\/j.gastro.2020.08.004","journal-title":"Gastroenterology"},{"key":"4509_CR103","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/hep4.1209","volume":"2","author":"MJ Mayo","year":"2018","unstructured":"Mayo MJ, Wigg AJ, Leggett BA, Arnold H, Thompson AJ, Weltman M, Carey EJ, Muir AJ, Ling L, Rossi SJ, DePaoli AM (2018) NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Commun 2:1037\u20131050. https:\/\/doi.org\/10.1002\/hep4.1209","journal-title":"Hepatol Commun"},{"key":"4509_CR104","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/acer.14619","volume":"45","author":"DJ Matye","year":"2021","unstructured":"Matye DJ, Li Y, Chen C, Chao X, Wang H, Ni H, Ding WX, Li T (2021) Gut-restricted apical sodium-dependent bile acid transporter inhibitor attenuates alcohol-induced liver steatosis and injury in mice. Alcohol Clin Exp Res 45:1188\u20131199. https:\/\/doi.org\/10.1111\/acer.14619","journal-title":"Alcohol Clin Exp Res"},{"key":"4509_CR105","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s12072-020-10070-w","volume":"14","author":"SJ Karpen","year":"2020","unstructured":"Karpen SJ, Kelly D, Mack C, Stein P (2020) Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int 14:677\u2013689. https:\/\/doi.org\/10.1007\/s12072-020-10070-w","journal-title":"Hepatol Int"},{"key":"4509_CR106","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jcmgh.2021.04.013","volume":"12","author":"DJ Matye","year":"2021","unstructured":"Matye DJ, Wang H, Luo W, Sharp RR, Chen C, Gu L, Jones KL, Ding WX, Friedman JE, Li T (2021) Combined ASBT inhibitor and FGF15 treatment improves therapeutic efficacy in experimental nonalcoholic steatohepatitis. Cell Mol Gastroenterol Hepatol 12:1001\u20131019. https:\/\/doi.org\/10.1016\/j.jcmgh.2021.04.013","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"4509_CR107","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/s0140-6736(17)30319-7","volume":"389","author":"VS Hegade","year":"2017","unstructured":"Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Thompson D, Richards D, Storey J, Dukes GE, Corrigan M, Oude Elferink RP, Beuers U, Hirschfield GM, Jones DE (2017) Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet 389:1114\u20131123. https:\/\/doi.org\/10.1016\/s0140-6736(17)30319-7","journal-title":"Lancet"},{"key":"4509_CR108","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/apt.15880","volume":"52","author":"A Dhanda","year":"2020","unstructured":"Dhanda A, Atkinson S, Vergis N, Enki D, Fisher A, Clough R, Cramp M, Thursz M (2020) Trace element deficiency is highly prevalent and associated with infection and mortality in patients with alcoholic hepatitis. Aliment Pharmacol Ther 52:537\u2013544. https:\/\/doi.org\/10.1111\/apt.15880","journal-title":"Aliment Pharmacol Ther"},{"key":"4509_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2020.06.006","volume":"227","author":"H Chu","year":"2021","unstructured":"Chu H, Jiang L, Gao B, Gautam N, Alamoudi JA, Lang S, Wang Y, Duan Y, Alnouti Y, Cable EE, Schnabl B (2021) The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice. Transl Res 227:1\u201314. https:\/\/doi.org\/10.1016\/j.trsl.2020.06.006","journal-title":"Transl Res"},{"key":"4509_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.02.033","author":"CL Bowlus","year":"2022","unstructured":"Bowlus CL, Galambos MR, Aspinall RJ, Hirschfield GM, Jones DEJ, D\u00f6rffel Y, Gordon SC, Harrison SA, Kremer AE, Mayo MJ, Thuluvath PJ, Levy C, Swain MG, Neff GW, Sheridan DA, Stanca CM, Berg CP, Goel A, Shiffman ML, Vierling JM et al (2022) A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2022.02.033","journal-title":"J Hepatol"},{"key":"4509_CR111","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/s2468-1253(17)30246-7","volume":"2","author":"D Jones","year":"2017","unstructured":"Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC, Odin JA, Sheridan D, W\u00f6rns MA, Clark V, Corless L, Hartmann H, Jonas ME, Kremer AE, Mells GF, Buggisch P, Freilich BL et al (2017) Seladelpar (MBX-8025), a selective ppar-\u03b4 agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol 2:716\u2013726. https:\/\/doi.org\/10.1016\/s2468-1253(17)30246-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4509_CR112","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jhep.2016.11.008","volume":"66","author":"G Ferrere","year":"2017","unstructured":"Ferrere G, Wrzosek L, Cailleux F, Turpin W, Puchois V, Spatz M, Ciocan D, Rainteau D, Humbert L, Hugot C, Gaudin F, Noordine ML, Robert V, Berrebi D, Thomas M, Naveau S, Perlemuter G, Cassard AM (2017) Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice. J Hepatol 66:806\u2013815. https:\/\/doi.org\/10.1016\/j.jhep.2016.11.008","journal-title":"J Hepatol"},{"key":"4509_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/cells11060968","author":"D Ciocan","year":"2022","unstructured":"Ciocan D, Spatz M, Trainel N, Hardonni\u00e8re K, Domenichini S, Mercier-Nom\u00e9 F, Desmons A, Humbert L, Durand S, Kroemer G, Lamazi\u00e8re A, Hugot C, Perlemuter G, Cassard AM (2022) Modulation of the bile acid enterohepatic cycle by intestinal microbiota alleviates alcohol liver disease. Cells. https:\/\/doi.org\/10.3390\/cells11060968","journal-title":"Cells"},{"key":"4509_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2021.117883","volume":"261","author":"AC Khorasani","year":"2021","unstructured":"Khorasani AC, Kouhfar F, Shojaosadati SA (2021) Pectin\/lignocellulose nanofibers\/chitin nanofibers bionanocomposite as an efficient biosorbent of cholesterol and bile salts. Carbohydr Polym 261:117883. https:\/\/doi.org\/10.1016\/j.carbpol.2021.117883","journal-title":"Carbohydr Polym"},{"key":"4509_CR115","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1136\/gutjnl-2020-321565","volume":"70","author":"L Wrzosek","year":"2021","unstructured":"Wrzosek L, Ciocan D, Hugot C, Spatz M, Dupeux M, Houron C, Lievin-Le Moal V, Puchois V, Ferrere G, Trainel N, Mercier-Nom\u00e9 F, Durand S, Kroemer G, Voican CS, Emond P, Straube M, Sokol H, Perlemuter G, Cassard AM (2021) Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury. Gut 70:1299\u20131308. https:\/\/doi.org\/10.1136\/gutjnl-2020-321565","journal-title":"Gut"},{"key":"4509_CR116","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1194\/jlr.M071183","volume":"57","author":"S Takahashi","year":"2016","unstructured":"Takahashi S, Fukami T, Masuo Y, Brocker CN, Xie C, Krausz KW, Wolf CR, Henderson CJ, Gonzalez FJ (2016) Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans. J Lipid Res 57:2130\u20132137. https:\/\/doi.org\/10.1194\/jlr.M071183","journal-title":"J Lipid Res"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-022-04509-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-022-04509-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-022-04509-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T08:31:10Z","timestamp":1663230670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-022-04509-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":116,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["4509"],"URL":"https:\/\/doi.org\/10.1007\/s00018-022-04509-6","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"assertion":[{"value":"20 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors agreed on the publication of the current version of manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"486"}}